The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

PerkinElmer

AUGUST 25, 2019

With no natural enemies left to stop tumor cells, they proliferate and lead to tumors that can even adapt to various treatments to evade immunity. The Results, Please Dr. Hinterneder’s research confirms that PD-L1 protein expression levels in human cells can be quickly and accurately assessed with the AlphaLISA human PD-L1 assay.

Protein Expression 52

Protein Expression Immune Response Treatment Research 52

Broad Institute

JUNE 27, 2024

By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. Vallabh soon found out that she inherited the same disease-causing mutation in the prion protein gene. Credit: Neumann EN, Bertozzi TM, et al.

Disease 142

Disease Therapies Engineering Clinical Trials 142

Drug Discovery World

NOVEMBER 8, 2023

Helmut Salih, MD, Professor for Translational Immunology, Medical Director, Clinical Collaboration Unit Translational Immunology, University Hospital Tuebingen and DKFZ Heidelberg, Germany; Co-Founder, TWYCE GmbH, on: ‘An optimised IgG-Based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers’. Claes Gustafsson, Ph.D,

Engineering 162

Engineering Protein Expression Therapies Science 162

The Pharma Data

MARCH 26, 2021

If approved, Tecentriq could offer people with a specific type of lung cancer a chemotherapy-free option in the first-line treatment setting. We remain committed to providing effective and tailored lung cancer treatment options, and this announcement is an important step toward this goal.”. months; hazard ratio [HR]=0.59, 95% CI: 0.40–0.89;

Treatment 52

Treatment Protein Expression Therapies Immune Response 52

The Pharma Data

MAY 4, 2021

Tecentriq monotherapy has been shown to improve overall survival in people with high PD-L1 expression, when compared to chemotherapy, and therefore represents a new treatment option for people living with this difficult-to-treat disease.”. 0.89; p=0.0106) in people with high PD-L1 expression (TC3 or IC3-wild-type [WT]).

Treatment 52

Treatment Therapies Disease Protein Expression 52